Swissmedic, the surveillance authority for medicines and medical devices, granted Linnea SA a narcotics license at the end of 2022.

This allows the company to help bring a pharmaceutical level of quality to this emerging cannabinoid industry, which is projected to grow from $28.26 billion in 2021 to $197.74 billion in 2028.

Linnea will begin producing GMP-certified high-THC active pharmaceutical ingredients (APIs) in 2023, becoming one of the …

Full story available on Benzinga.com